Protein degrader developer Lycia seeks $228M in US IPO
Lycia, a South San Francisco biotech, detailed plans for a US listing at a valuation of up to $885.6M. Information is according to Seeking Alpha.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Lycia Therapeutics, a biotech focused on protein degrader therapies, said on Tuesday it plans to go public in the US. According to Seeking Alpha, the company's valuation could reach up to $885.6M.
At the midpoint of its $16 to $18 per share price range, Lycia expects to raise about $227.8M in net proceeds from selling 14.7M shares. If underwriters fully exercise their option to buy about 2.2M additional shares, net proceeds would rise to about $262.7M. The shares would trade on the Nasdaq Global Select Market under the symbol LYCA.
why it matters
The proceeds are earmarked, among other things, for clinical development of lead assets LCA-0061 and LCA-0321, aimed at allergic diseases and Graves' disease. Both candidates are at an early stage, with further Phase 1 data expected next year. For markets, deals like this signal how willing investors are to fund early-stage biotech projects.
market impact
Biotech sector and US IPO market: a sizable listing signals investor appetite for risk and early-stage drug developers.
tags
instruments
sources
- Protein degrader drug developer Lycia seeks $228M in U.S. IPO — Seeking Alpha, 20 October 2026 at 19:33 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗